Login / Signup

High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects.

Huawei TongJia HuangQingquan XiaoBingbing HeXue DongYuanhua LiuXiali YangDingyi HanZikang WangXuchen WangWenqin YingRunze ZhangYu WeiChunlong XuYingsi ZhouYanfei LiMinqing CaiQifang WangMingxing XueGuoling LiKailun FangHainan ZhangHui Yang
Published in: Nature biotechnology (2022)
CRISPR-Cas13 systems have recently been used for targeted RNA degradation in various organisms. However, collateral degradation of bystander RNAs has limited their in vivo applications. Here, we design a dual-fluorescence reporter system for detecting collateral effects and screening Cas13 variants in mammalian cells. Among over 200 engineered variants, several Cas13 variants including Cas13d and Cas13X exhibit efficient on-target activity but markedly reduced collateral activity. Furthermore, transcriptome-wide off-targets and cell growth arrest induced by Cas13 are absent for these variants. High-fidelity Cas13 variants show similar RNA knockdown activity to wild-type Cas13 but no detectable collateral damage in transgenic mice or adeno-associated-virus-mediated somatic cell targeting. Thus, high-fidelity Cas13 variants with minimal collateral effects are now available for targeted degradation of RNAs in basic research and therapeutic applications.
Keyphrases
  • crispr cas
  • genome editing
  • copy number
  • cancer therapy
  • genome wide
  • dna methylation
  • oxidative stress
  • multidrug resistant
  • cell cycle
  • gram negative